AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home International Journal of Oral Science Article
PDF (5.5 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Tetrahedral framework nucleic acid carrying angiogenic peptide prevents bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis

Dan Zhao1,, Dexuan Xiao1,, Mengting Liu1, Jiajie Li1, Shuanglin Peng2, Qing He2, Yue Sun1, Jingang Xiao2( ), Yunfeng Lin1 ( )
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China
Department of Oral and Maxillofacial Surgery, The Affiliated Stomatology Hospital of Southwest Medical University, Luzhou, China

These authors contributed equally: Dan Zhao, Dexuan Xiao

Show Author Information

Abstract

The significant clinical feature of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is the exposure of the necrotic jaw. Other clinical manifestations include jaw pain, swelling, abscess, and skin fistula, which seriously affect the patients’ life, and there is no radical cure. Thus, new methods need to be found to prevent the occurrence of BRONJ. Here, a novel nanoparticle, tFNA-KLT, was successfully synthesized by us, in which the nanoparticle tetrahedral framework nucleic acid (tFNA) was used for carrying angiogenic peptide, KLT, and then further enhanced angiogenesis. TFNA-KLT possessed the same characteristics as tFNA, such as simple synthesis, stable structure, and good biocompatibility. Meanwhile, tFNA enhanced the stability of KLT and carried more KLT to interact with endothelial cells. First, it was confirmed that tFNA-KLT had the superior angiogenic ability to tFNA and KLT both in vitro and in vivo. Then we apply tFNA-KLT to the prevention of BRONJ. The results showed that tFNA-KLT can effectively prevent the occurrence of BRONJ by accelerating angiogenesis. In summary, the prepared novel nanoparticle, tFNA-KLT, was firstly synthesized by us. It was also firstly confirmed by us that tFNA-KLT significantly enhanced angiogenesis and can effectively prevent the occurrence of BRONJ by accelerating angiogenesis, thus providing a new avenue for the prevention of BRONJ and a new choice for therapeutic angiogenesis.

References

1

Mavrokokki, T., Cheng, A., Stein, B. & Goss, A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J. Oral. Maxil. Surg. 65, 415–423 (2007).
Crossref Google Scholar
2

Singh, M. & Gonegandla, G. S. Bisphosphonate induced osteonecrosis of the jaws (BIONJ). J. Maxil. Oral. Surg. 19, 162–167 (2020).
Crossref Google Scholar
3

Falk, W. et al. BRONJ- related jaw bone is associated with increased Dlx-5 and suppressed osteopontin—implication in the site-specific alteration of angiogenesis and bone turnover by bisphosphonates. Clin. Oral. Invest. 19, 1289–1298 (2015).
Crossref Google Scholar
4

Kilic, E. & Doganay, O. Current management concepts for bisphosphonate-related osteonecrosis of the jaw: a review. Gen. Dent. 66, e1–e5 (2018).
Google Scholar
5

Chang, J., Hakam, A. E. & Mccauley, L. K. Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr. Osteoporos. Rep. 16, 584–595 (2018).
Crossref Google Scholar
6

Di Salvatore, M. et al. Barone. Anti‐tumor and anti‐angiogenetic effects of zoledronic acid on human non‐small‐cell lung cancer cell line. Cell Proliferat. 44, 139–146 (2011).
Crossref Google Scholar
7

Loïc, L. et al. Comparative study of neoadjuvant chemotherapy with and without Zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: the NEOZOL study. Clin. Breast Cancer 18, e1311–e1321 (2018).
Crossref Google Scholar
8

Ferretti, G. et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69, 35–43 (2005).
Crossref Google Scholar
9

James, L. B. et al. Correlation of changes in the mandible and retina/choroid vasculature of a rat model of BRONJ. J. Cranio-Maxill. Surg. 43, 1144–1150 (2015).
Crossref Google Scholar
10

Dan, Z. et al. Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization. ACS Appl. Mater. Inter. 12, 44508–44522 (2020).
Crossref Google Scholar
11

Kuroshima, S., Nakajima, K., Sasaki, M., Takashi, I. & Sawase, T. Systemic administration of quality- and quantity-controlled pbmncs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice. Stem Cell Res. Ther. 10, 209 (2019).
Crossref Google Scholar
12

Robert, E. M., Yoh, S., Michel, F. & Vishtasb, B. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral. Maxill. Surg. 63, 1567–1576 (2005).
Crossref Google Scholar
13

Fliefel, R., Tröltzsch, M., Kühnisch, J., Ehrenfeld, M. & Otto, S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int. J. Oral. Max. Surg. 44, 568–585 (2015).
Crossref Google Scholar
14

Matsumoto, A. et al. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin. Oral. Invest. 21, 1–8 (2017).
Crossref Google Scholar
15

Sao-Shen, L. et al. Immediate hyperbaric oxygen after tooth extraction ameliorates bisphosphonate-related osteonecrotic lesion in rats. J. Periodontol. 90, 1449–1456 (2019).
Crossref Google Scholar
16

Voss, P. J. et al. Treatment of stage ii medication-related osteonecrosis of the jaw with neurectomy and autologous bone marrow mesenchymal stem cells. Odontology 105, 484–493 (2017).
Crossref Google Scholar
17

Cardoso, C. L., Curra, C., Curi, M. M., Matsumoto, M. A. & Jnior, O. F. Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: microtomographic, microscopic, and immunohistochemical analyses. Braz. Oral. Res. 33, e050 (2019).
Crossref Google Scholar
18

Julie, G. Angiogenesis in fracture repair. Clin. Orthop. Relat. R. 355, 82–89 (1998).
Google Scholar
19

Hu, K. & Olsen, B. R. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone 91, 30–38 (2016).
Crossref Google Scholar
20

D’Andrea, L. et al. Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc. Natl Acad. Sci. USA 102, 14215–14220 (2005).
Crossref Google Scholar
21

Santulli, G. et al. In vivo properties of the proangiogenic peptide QK. J. Trans. Med. 7, 41–50 (2009).
Crossref Google Scholar
22

Finetti, F., Basile, A., Capasso, D., Gaetano, S. D. & D’Andrea, L. D. Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochem. Pharmacol. 84, 303–311 (2012).
Crossref Google Scholar
23

Pensa, N. W., Curry, A. S., Reddy, M. S. & Bellis, S. L. Sustained delivery of the angiogenic QK peptide through the use of polyglutamate domains to control peptide release from bone graft materials. J. Biomed. Mater. Res. A 107, 2764–2773 (2019).
Crossref Google Scholar
24

Wenjuan, M. et al. Biomimetic nanoerythrosome-coated aptamer-DNA tetrahedron/maytansine conjugates: pH-responsive and targeted cytotoxicity for HER2-positive breast cancer. Adv. Mater. e2109609 (2022).
Google Scholar
25

Bowen, Z. et al. Facilitating in-situ tumor imaging with a tetrahedral DNA framework-enhanced hybridization chain reaction probe. Adv. Funct. Mater. 2109728 (2022).
Google Scholar
26

Mi, Z. et al. A DNA nanostructure-based neuroprotectant against neuronal apoptosis via inhibiting toll-like receptor 2 signaling pathway in acute ischemic stroke. ACS Nano. 16, 1456–1470 (2022).
Crossref Google Scholar
27

Yuhao, L. et al. Tetrahedral framework nucleic acids deliver antimicrobial peptides with improved effects and less susceptibility to bacterial degradation. Nano Lett. 20, 3602–3610 (2020).
Crossref Google Scholar
28

Mengting, L. et al. Enhanced penetrability of a tetrahedral framework nucleic acid by modification with iRGD for DOX-targeted delivery to triple negative breast cancer. ACS Appl. Mater. Inter. 13, 25825–25835 (2021).
Crossref Google Scholar
29

Wood, J. et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302, 1055–1061 (2002).
Crossref Google Scholar
30

Pabst, A. M., Ziebart, T., Ackermann, M., Konerding, M. A. & Walter, C. Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D matrigel assay. Clin. Oral. Invest. 18, 1015–1022 (2014).
Crossref Google Scholar
31

Dan, Z. et al. Tetrahedral DNA nanostructure promotes endothelial cell proliferation, migration, and angiogenesis via notch signaling pathway. ACS Appl. Mater. Inter. 10, 37911–37918 (2018).
Crossref Google Scholar
32

Shiyu, L. et al. Antioxidative and angiogenesis-promoting effects of tetrahedral framework nucleic acids in diabetic wound healing with activation of the Akt/Nrf2/HO-1 pathway. ACS Appl. Mater. Inter. 12, 11397–11408 (2020).
Crossref Google Scholar
33

Dan, Z. et al. Angiogenic aptamer-modified tetrahedral framework nucleic acid promotes angiogenesis in vitro and in vivo. ACS Appl. Mater. Inter. 13, 29439–29449 (2021).
Crossref Google Scholar
34

Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873–887 (2011).
Crossref Google Scholar
35

Tao, Z. et al. Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment. Nat. Protoc. 15, 2728–2757 (2020).
Crossref Google Scholar
36

Tao, Z., Taoran, T. & Yunfeng, L. Functionalizing framework nucleic acid-based nanostructures for biomedical application. Adv. Mater. e2107820 (2021).
Google Scholar
37

Yun, W. et al. Tetrahedral framework nucleic acids can alleviate taurocholate-induced severe acute pancreatitis and its subsequent multi-organ injury in mice. Nano Lett. 22, 1759–1768 (2022).
Crossref Google Scholar
38

Jun, L. et al. Repair of infected bone defect with clindamycin-tetrahedral DNA nanostructure complex-loaded 3D bioprinted hybrid scaffold. Chem. Eng. J. 435, 134855 (2022).
Crossref Google Scholar
39

Mei, Z. et al. Anti-inflammatory activity of curcumin-loaded tetrahedral framework nucleic acids on acute gouty. Arthritis Bioact. Mater. 8, 368–380 (2022).
Crossref Google Scholar
40

Xin, Q. et al. Tetrahedral framework nucleic acids-based delivery of microRNA-155 inhibits choroidal neovascularization by regulating the polarization of macrophages. Bioact. Mater. 14, 134–144 (2022).
Crossref Google Scholar
41

Silva, M. L. et al. Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy—histomorphometric and immunohistochemical analysis. Clin. Oral. Invest. 21, 199–210 (2017).
Crossref Google Scholar
42

Rupel, K. et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral. Oncol. 50, 1049–1057 (2014).
Crossref Google Scholar
43

Rodolfo, M. et al. Conservative surgical treatment of bisphosphonate-related osteonecrosis of the jaw with Er,Cr:YSGG laser and platelet-rich plasma: a longitudinal study. Biomed. Res. Int. 2018, 1–10 (2018).
Crossref Google Scholar
44

Martins, M. A. T. et al. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral. Oncol. 48, 79–84 (2012).
Crossref Google Scholar
45

Longo, F. et al. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Inter. J. Dent. 2014, 1–7 (2014).
Crossref Google Scholar
46

Maluf, G., Caldas, R. J., Fregnani, E. R. & Santos, P. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. Inter. J. Implant Dent. 5, 1–6 (2019).
Crossref Google Scholar
47

Mohamed, H. A. M., Nielsen, C. E. N. & Schiodt, M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. a report of 7 cases from the Copenhagen cohort. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 125, 157–163 (2017).
Crossref Google Scholar
48

Xiaoyuan, J. et al. Protein-mimicking nanoparticles for a cellular regulation of homeostasis. ACS Appl. Mater. inter, 13, 31331–31336 (2021).
Crossref Google Scholar
49

Yanfeng, Z. et al. An organelle‐specific nanozyme for diabetes care in genetically or diet‐induced models. Adv. Mater., 32, 2003708 (2020).
Crossref Google Scholar
International Journal of Oral Science
Volume 14,
2022
Article number: 23
DOI: 10.1038/s41368-022-00171-7
Cite this article:
Zhao D, Xiao D, Liu M, et al. Tetrahedral framework nucleic acid carrying angiogenic peptide prevents bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis. International Journal of Oral Science, 2022, 14: 23. https://doi.org/10.1038/s41368-022-00171-7

153

Views

1

Downloads

27

Crossref

23

Web of Science

28

Scopus

Altmetrics
Received: 22 December 2021
Revised: 05 March 2022
Accepted: 10 March 2022
Published: 27 April 2022
© The Author(s) 2022

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Return